Authors: Dore, Gregory J., Conway, Brian, Luo, Yan, Janczewska, Ewa, Knysz, Brygida, Liu, Streinu-Cercel, Adrian, Caruntu, Florin Alexandru, Curescu, Manuela, Skoien, Richard, Ghesquiere, Wayne, Mazur, Włodzimierz, Soza, Alejandro, Fuster, Francisco, Greenbloom, Susan, Motoc, Adriana, Arama, Victoria, Shaw, David, Tornai, Istvan, Sasadeusz, Joseph, Dalgard, Olav, Sullivan, Danielle, Xuan, Kapoor, Mudra, Campbell, Andrew, Podsadecki, Thomas
Venue: Journal of Hepatology
Type: Publication
Abstract: Background & AimsTelaprevir plus pegylated interferon/ribavirin (TPV+PegIFN/RBV) remains a therapeutic option for chronic hepatitis C virus (HCV) genotype (GT) 1 infection in many regions. We conducted two open-label, phase IIIb trials comparing safety and efficacy of all-oral ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin (OBV/PTV/r+DSV±RBV) and TPV+PegIFN/RBV.MethodsTreatment-naïve (MALACHITE-I) or PegIFN/RBV-experienced (MALACHITE-II) non-cirrhotic, chronic HCV GT1-infected patients were randomized to OBV/PTV/r+DSV+weight-based...
(read more)
Topics: 
Gastroenterology
Internal medicine
Loading (it may take a couple of seconds)...
Loading (it may take a couple of seconds)...